Benralizumab

SAN DIEGO — Patients with severe asthma initiated dupilumab and tezepelumab treatment more often than other biologics between 2022 and 2023, according to a poster presented here.

SAN DIEGO — Remission persisted through 104 weeks for most patients with eosinophilic granulomatosis with polyangiitis who used benralizumab, according to a poster presented here.

SAN DIEGO — Across six asthma biologics, adherence differed by the therapy given and was often low or irregular based on three adherence measures, according to a presentation here.

In this video, Rula Hajj-Ali, MD discusses the latest developments in the study and treatment of vasculitis.

Among adults with severe eosinophilic asthma and previous biologic use, benralizumab for 48 weeks aided in reducing exacerbations and improving asthma symptom control, according to results published in European Respiratory Journal.

Receiving a benralizumab injection during an acute asthma or COPD exacerbation with a blood eosinophil count of at least 300 cells/µL led to fewertreatment failures, according to results published in The Lancet Respiratory Medicine.

BOSTON — Patients taking benralizumab experienced more asthma exacerbations than patients taking mepolizumab, according to an abstract presented at the CHEST Annual Meeting.

Patients with severe asthma and small airways disease did not respond as well to omalizumab treatment, according to a poster presented at the European Respiratory Society International Congress.

The FDA approved AstraZeneca’s Fasenra for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis, or EGPA, according to a company press release.

Adults with severe asthma using a biologic therapy for the first time experienced changes in body composition parameters at 1 year, according to a research letter published in Annals of the American Thoracic Society.